原发性脑肿瘤合并癫痫患者的发作特征
该回顾性研究基于Clalit Dan–Petah Tikva County数据库(2000–2019年,覆盖155万余人),分析成人原发性脑肿瘤合并癫痫的发作控制与管理。结果显示胶质瘤癫痫率高于脑膜瘤,多数癫痫病例与良性肿瘤相关,耐药性癫痫高风险患者识别率和专科转诊率均极低,无人接受癫痫手术评估。
要点
- 胶质瘤患者癫痫发生率高于脑膜瘤,多数癫痫病例与良性肿瘤相关。
- 耐药性癫痫高风险患者中仅极少数获得正式诊断和专科随访。
- 无一例难治性癫痫患者接受癫痫手术评估,存在显著治疗缺口。
核心结论
- 尽管肿瘤控制充分,许多肿瘤相关癫痫患者在切除和肿瘤治疗后仍继续发作,原因包括管理欠佳或难治性。
- 耐药性癫痫识别不足和专科癫痫中心转诊率低,凸显显著治疗缺口。
- 需要改进转诊路径和综合评估以优化该人群的癫痫结局。
研究设计与样本
- 回顾性研究,基于Clalit Dan–Petah Tikva County数据库(2000–2019年),覆盖1,557,764人。
- 通过ICD-10编码识别成人原发性脑肿瘤合并癫痫患者。
- 通过抗癫痫药物处方、随访、住院和专科癫痫门诊评估来评价癫痫控制与管理。
主要发现
- 在1,557,764人中,17,225人(1.1%)诊断为脑肿瘤,其中14.7%(n=2,532)合并继发性癫痫。
- 胶质瘤患者癫痫率为29.2%(n=878),脑膜瘤为13.1%(n=1,417)。
- 多数癫痫病例与良性肿瘤相关(65.6%,n=1,661)。
- 9.7%(n=1,672)被归类为耐药性癫痫高风险,但仅0.5%(n=89)有正式诊断。
- 正式诊断者中仅12人(0.7%)在专科癫痫门诊随访,其余由社区神经科医生、肿瘤科医生、神经外科医生或初级保健医生管理。
临床怎么用
- 对脑肿瘤合并癫痫患者应提高耐药性癫痫的识别意识。
- 对耐药性癫痫高风险患者应及时转诊至专科癫痫中心评估。
- 难治性癫痫患者应考虑癫痫手术评估以优化发作控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Epilepsy is among the most prevalent neurological disorders, with one in 10 people experiencing a seizure in their lifetime. In adults, brain tumors are a common cause. While tumor-control outcomes are well studied, less is known about seizure control in this population. METHODS: We retrospectively reviewed the Clalit Dan–Petah Tikva County database (2000–2019), covering 1.55 million patients. Adults with primary brain tumors and epilepsy were identified by ICD-10 codes. Seizure control and management were assessed through anti-seizure medication (ASM) prescriptions, follow-up care, hospitalizations, and evaluation by specialized epilepsy clinics. RESULTS: Among 1,557,764 individuals, 17,225 (1.1%) adults were diagnosed with a brain tumor, of whom 14.7% (n = 2,532) had secondary epilepsy. Glioma patients had more than double the epilepsy rate (29.2%, n = 878) compared to meningioma (13.1%, n = 1,417). Most epilepsy cases were associated with benign tumors (65.6%, n = 1,661). Overall, 9.7% (n = 1,672) were classified as high-risk for drug-resistant epilepsy (DRE), yet only 0.5% (n = 89) had a formal diagnosis. Of these, just 12 (0.7%) received follow-up at a specialized epilepsy clinic; the remainder were managed by community neurologists, oncologists, neurosurgeons, or primary care physicians. None of the patients with intractable epilepsy underwent evaluation for epilepsy surgery. CONCLUSION: Despite adequate tumor control, many patients with tumor-related epilepsy continue to experience seizures after resection and oncological treatment, due to suboptimal management or intractability. Under-recognition of DRE and low referral rates to specialized epilepsy centers highlight a significant treatment gap. Improved referral pathways and comprehensive evaluations are needed to optimize seizure outcomes in this population.
引用
- Vegh L, Benninger F, Tamir I, et al. Seizure characteristics in epilepsy patients with a primary brain tumor. J Neurooncol. 2025. PMID: 41258589. doi:10.1007/s11060-025-05331-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。